JAMA and JAMA Network Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, spoke with Mark Cuban, entrepreneur and cofounder of the Mark Cuban Cost Plus Drugs Company, about pharmaceutical pricing.
《美国医学会杂志》和《美国医学会杂志》网络主编Kirsten Bibbins-Domingo博士、医学博士、MAS与Mark Cuban Cost Plus Drugs Company的企业家和联合创始人Mark Cuban就药品定价进行了交谈。
{"title":"Pharmaceutical Pricing—JAMA Talks With Mark Cuban","authors":"Kirsten Bibbins-Domingo","doi":"10.1001/jama.2025.25505","DOIUrl":"https://doi.org/10.1001/jama.2025.25505","url":null,"abstract":"<jats:italic toggle=\"yes\">JAMA</jats:italic> and JAMA Network Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, spoke with Mark Cuban, entrepreneur and cofounder of the Mark Cuban Cost Plus Drugs Company, about pharmaceutical pricing.","PeriodicalId":518009,"journal":{"name":"JAMA","volume":"47 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146160436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Daniela Diego, Audrey J. Gaskins, Heather S. Hipp, Jennifer F. Kawwass
This study compares embryo transfer and pregnancy outcomes among US same-sex female couples undergoing reciprocal and autologous oocyte in vitro fertilization (IVF) cycles.
本研究比较了美国同性女性伴侣进行互惠和自体卵母细胞体外受精（IVF）周期的胚胎移植和妊娠结局。
{"title":"Outcomes of Same-Sex Female Couples Pursuing Autologous and Reciprocal In Vitro Fertilization","authors":"Daniela Diego, Audrey J. Gaskins, Heather S. Hipp, Jennifer F. Kawwass","doi":"10.1001/jama.2025.26962","DOIUrl":"https://doi.org/10.1001/jama.2025.26962","url":null,"abstract":"This study compares embryo transfer and pregnancy outcomes among US same-sex female couples undergoing reciprocal and autologous oocyte in vitro fertilization (IVF) cycles.","PeriodicalId":518009,"journal":{"name":"JAMA","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146160433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
In this narrative medicine essay, a pediatrician and former medical school dean offers 3 steps for clinicians on how to adapt their cognitive evaluations to the abilities of their patients, in this case his wife who has stage 6 Alzheimer disease.
{"title":"When Protocol Meets Reality","authors":"Wesley Burks","doi":"10.1001/jama.2026.0064","DOIUrl":"https://doi.org/10.1001/jama.2026.0064","url":null,"abstract":"In this narrative medicine essay, a pediatrician and former medical school dean offers 3 steps for clinicians on how to adapt their cognitive evaluations to the abilities of their patients, in this case his wife who has stage 6 Alzheimer disease.","PeriodicalId":518009,"journal":{"name":"JAMA","volume":"47 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146160431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This Viewpoint examines 3 dimensions of Medicare’s quality measurement enterprise regarding clinical care assessment, provider network performance, and quality improvement incentivization and outlines reforms to restore accountability.
{"title":"Medicare Advantage and Quality Measurement—A System at Risk","authors":"Adam A. Markovitz, Eve A. Kerr, Jeffrey A. Buck","doi":"10.1001/jama.2026.0369","DOIUrl":"https://doi.org/10.1001/jama.2026.0369","url":null,"abstract":"This Viewpoint examines 3 dimensions of Medicare’s quality measurement enterprise regarding clinical care assessment, provider network performance, and quality improvement incentivization and outlines reforms to restore accountability.","PeriodicalId":518009,"journal":{"name":"JAMA","volume":"98 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146160432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jennifer L. Pomeranz, Emily M. Broad Leib, Dariush Mozaffarian
This Viewpoint discusses the US Food and Drug Administration’s authority over food safety, including prior regulations surrounding ingredients, preemption, and federal vs state laws.
{"title":"Food Ingredients, State Actions, and Federal Preemption","authors":"Jennifer L. Pomeranz, Emily M. Broad Leib, Dariush Mozaffarian","doi":"10.1001/jama.2026.0366","DOIUrl":"https://doi.org/10.1001/jama.2026.0366","url":null,"abstract":"This Viewpoint discusses the US Food and Drug Administration’s authority over food safety, including prior regulations surrounding ingredients, preemption, and federal vs state laws.","PeriodicalId":518009,"journal":{"name":"JAMA","volume":"37 2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146152746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Miriam T. H. Harris, Zoe M. Weinstein, Alexander Y. Walley
Importance Opioid use disorder (OUD) involves compulsive opioid use that causes substantial distress or impairment at work, school, or home. OUD, which is the third most prevalent substance use disorder worldwide, affected an estimated 3.7% of US adults (9 367 000) in 2022 and caused 53 774 deaths in the US in 2024. Medications for opioid use disorder (MOUD) reduce morbidity and mortality. Individuals with OUD also benefit from medications to treat opioid withdrawal and reverse acute opioid overdose. Observations Methadone, buprenorphine, and naltrexone are medications approved by the US Food and Drug Administration (FDA) to reduce unregulated opioid use. Methadone and buprenorphine reduce the risks of overdose and all-cause mortality. However, only 25.1% of people in the US with OUD were treated with these medications in 2022. MOUD should be selected based on shared decision-making that considers availability and convenience of treatment options and patient preferences. Buprenorphine and naltrexone are prescribed in office-based settings and can be taken at home. Outpatients with OUD in the US can only obtain methadone in person at federally regulated clinics. After stopping or substantially reducing use of opioids, individuals with OUD develop symptoms of opioid withdrawal, such as anxiety, insomnia, pain, nausea, vomiting, and diarrhea. Medications for opioid withdrawal include opioid agonists (eg, methadone and buprenorphine), α 2 -receptor agonists (eg, lofexidine and clonidine), and medications to treat pain (ibuprofen) and nausea (ondansetron). Individuals being treated for acute withdrawal should also be prescribed MOUD to decrease the risk of all-cause mortality (adjusted hazard ratio, 0.52; 95% CI, 0.42-0.63 for MOUD vs no MOUD). Individuals who use opioids may develop opioid overdose, which can cause respiratory depression, stupor, and, if severe, coma and death. Opioid overdose can be treated or can be reversed with naloxone, an opioid antagonist that is FDA approved and should be administered at the lowest dose needed to restore a normal respiratory rate (eg, naloxone 0.4 mg intramuscularly or 2-4 mg intranasally). Community-wide distribution of naloxone to people who use opioids and their social networks has been associated with 25% to 46% lower community opioid overdose rates. Conclusions and Relevance All individuals with OUD should be offered treatment with MOUD to reduce opioid use. Methadone and buprenorphine decrease opioid-associated and all-cause mortality in patients with OUD. Opioid withdrawal symptoms may be treated with opioid agonists, α 2 -receptor agonists, and medications for pain and nausea. All individuals with OUD should have access to opioid antagonists, such as naloxone, to treat opioid overdose.
{"title":"Medications for Opioid Use Disorder, Opioid Withdrawal, and Opioid Overdose","authors":"Miriam T. H. Harris, Zoe M. Weinstein, Alexander Y. Walley","doi":"10.1001/jama.2025.26348","DOIUrl":"https://doi.org/10.1001/jama.2025.26348","url":null,"abstract":"Importance Opioid use disorder (OUD) involves compulsive opioid use that causes substantial distress or impairment at work, school, or home. OUD, which is the third most prevalent substance use disorder worldwide, affected an estimated 3.7% of US adults (9 367 000) in 2022 and caused 53 774 deaths in the US in 2024. Medications for opioid use disorder (MOUD) reduce morbidity and mortality. Individuals with OUD also benefit from medications to treat opioid withdrawal and reverse acute opioid overdose. Observations Methadone, buprenorphine, and naltrexone are medications approved by the US Food and Drug Administration (FDA) to reduce unregulated opioid use. Methadone and buprenorphine reduce the risks of overdose and all-cause mortality. However, only 25.1% of people in the US with OUD were treated with these medications in 2022. MOUD should be selected based on shared decision-making that considers availability and convenience of treatment options and patient preferences. Buprenorphine and naltrexone are prescribed in office-based settings and can be taken at home. Outpatients with OUD in the US can only obtain methadone in person at federally regulated clinics. After stopping or substantially reducing use of opioids, individuals with OUD develop symptoms of opioid withdrawal, such as anxiety, insomnia, pain, nausea, vomiting, and diarrhea. Medications for opioid withdrawal include opioid agonists (eg, methadone and buprenorphine), α <jats:sub>2</jats:sub> -receptor agonists (eg, lofexidine and clonidine), and medications to treat pain (ibuprofen) and nausea (ondansetron). Individuals being treated for acute withdrawal should also be prescribed MOUD to decrease the risk of all-cause mortality (adjusted hazard ratio, 0.52; 95% CI, 0.42-0.63 for MOUD vs no MOUD). Individuals who use opioids may develop opioid overdose, which can cause respiratory depression, stupor, and, if severe, coma and death. Opioid overdose can be treated or can be reversed with naloxone, an opioid antagonist that is FDA approved and should be administered at the lowest dose needed to restore a normal respiratory rate (eg, naloxone 0.4 mg intramuscularly or 2-4 mg intranasally). Community-wide distribution of naloxone to people who use opioids and their social networks has been associated with 25% to 46% lower community opioid overdose rates. Conclusions and Relevance All individuals with OUD should be offered treatment with MOUD to reduce opioid use. Methadone and buprenorphine decrease opioid-associated and all-cause mortality in patients with OUD. Opioid withdrawal symptoms may be treated with opioid agonists, α <jats:sub>2</jats:sub> -receptor agonists, and medications for pain and nausea. All individuals with OUD should have access to opioid antagonists, such as naloxone, to treat opioid overdose.","PeriodicalId":518009,"journal":{"name":"JAMA","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146153312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Carmel Shachar, David Blumenthal, I. Glenn Cohen, Nicole Huberfeld
This Viewpoint discusses the executive order signed by President Trump regarding a national policy framework for artificial intelligence (AI), including what it means for medical AI regulation, the legal questions it raises, and the merits of state-level experimentation in health care regulation.
{"title":"Preemption at the Intersection of Health Care and Artificial Intelligence","authors":"Carmel Shachar, David Blumenthal, I. Glenn Cohen, Nicole Huberfeld","doi":"10.1001/jama.2026.0061","DOIUrl":"https://doi.org/10.1001/jama.2026.0061","url":null,"abstract":"This Viewpoint discusses the executive order signed by President Trump regarding a national policy framework for artificial intelligence (AI), including what it means for medical AI regulation, the legal questions it raises, and the merits of state-level experimentation in health care regulation.","PeriodicalId":518009,"journal":{"name":"JAMA","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146152747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This Viewpoint discusses the need to develop systematic review processes for medications during pregnancy, including routine randomized clinical trials (RCTs), rather than relying on observational study data.
{"title":"Why It Is Unethical Not to Conduct Randomized Trials in Pregnancy","authors":"Alyssa Bilinski","doi":"10.1001/jama.2026.0805","DOIUrl":"https://doi.org/10.1001/jama.2026.0805","url":null,"abstract":"This Viewpoint discusses the need to develop systematic review processes for medications during pregnancy, including routine randomized clinical trials (RCTs), rather than relying on observational study data.","PeriodicalId":518009,"journal":{"name":"JAMA","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146146212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This Viewpoint discusses the benefits and risks of systemic hormone therapy in breast cancer survivors following the US Food and Drug Administration’s removal of black box warnings from menopausal hormone therapy.
{"title":"What Systemic Hormone Therapy Black Box Removal Means for Breast Cancer Survivors","authors":"Versha Pleasant, Kari Ring","doi":"10.1001/jama.2026.0025","DOIUrl":"https://doi.org/10.1001/jama.2026.0025","url":null,"abstract":"This Viewpoint discusses the benefits and risks of systemic hormone therapy in breast cancer survivors following the US Food and Drug Administration’s removal of black box warnings from menopausal hormone therapy.","PeriodicalId":518009,"journal":{"name":"JAMA","volume":"89 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146121848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
In this narrative medicine essay, a critical care physician who recovered from a critical illness reflects on the importance of empathy and how patients and families can feel and see things physicians can’t.
{"title":"Building Empathy","authors":"Ian J. Barbash","doi":"10.1001/jama.2026.0009","DOIUrl":"https://doi.org/10.1001/jama.2026.0009","url":null,"abstract":"In this narrative medicine essay, a critical care physician who recovered from a critical illness reflects on the importance of empathy and how patients and families can feel and see things physicians can’t.","PeriodicalId":518009,"journal":{"name":"JAMA","volume":"46 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146121849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：